An injectable monoclonal antibody that targets the insulin-like growth factor I receptor improved proptosis in more than half of people with chronic thyroid eye disease, according to topline results ...
Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease May 5, 2026 8:00 ...
By Siddhi Mahatole May 5 (Reuters) - Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the ...
A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to ...
THE FOREIGNER EXPERIENCE, a one-night tribute concert at the Sitnik Theatre in Hackettstown, NJ, with proceeds benefiting the ...
UniverSoul Circus is back in Atlanta for the first time since 2024, setting up its Big Top at the former Turner Field Grey ...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today ...
WPBF Channel 25 on MSN
Stroke awareness: What doctors want people to know
Stroke awareness; what doctors want people to know ...
Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by ...
UFC heavyweight champion Tom Aspinall has been sidelined for the past seven months unable to spar after suffering injuries to ...
"I also wear a glucose monitor, so I know what exercise does to me [and] to my blood sugar." ...
Tapia, MD, PhD, discusses the results of the ADAPT OCULUS trial, which found promising results for treating patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results